10 research outputs found
Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro
No full textInvestigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension
No full text
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation
No full textSoil geochemistry as a tool for the origin investigation and environmental evaluation of urban parks in Mashhad city, NE of Iran
No full textDynamic development of metabolic syndrome and its risk prediction in Chinese population: a longitudinal study using Markov model
No full textGeriatric Oncology
No full textThe decrease in muscle mass and strength represents one of the most relevant descriptor of physiological aging. Sarcopenia is the term coined to indicate the pathologic loss of skeletal muscle mass and strength/function during aging. The skeletal muscle decline has a multifactorial origin, involving lifestyle habits, disease triggers, and age-dependent biological changes. This phenomenon is part of the geriatric background and is today starting to disseminate in other specialties dealing with the complexity of frail older persons. In the oncology field, the interest in muscle wasting has mostly been focused on the clinical entity of cancer cachexia, a complex metabolic syndrome characterized by severe muscle loss, systemic inflammation, and malnutrition. The study of body composition in the oncological setting is crucial and may become one of the main characterizations of the oncogeriatric field, where clinical and research actions have to be designed taking into account the consequences of the aging process
